Md Yuzaiful Md Yusof Yuz6Yusof
1 year 1 month ago
#EULAR2025 Abstr#OP0002 Promising new mode of action therapy for #myositis. Phase 2 RCT of efgartigimod (FcRn-i; coformulated with recombinant PH20) showed improvement in TIS & other key endpoints vs PBO at Wk24. Injection reaction common (23%). Will proceed to Phase 3 @RheumNow https://t.co/SuMolfcDkS
Janet Pope Janetbirdope
1 year 1 month ago
Pain & age predict outcomes in #osteoarthritis
In a #cohort of 92 pts with #knee #OA
Factors were studied for response
Better
✅#NSAIDs or #acetaminophen v #opiates
✅Older
✅Lower #WOMAC PAIN & no sensitization
🤔help RCT inclusion
#EULAR2025 @RheumNow POS0612 @eular_org https://t.co/9I2JN9sgUe
Janet Pope Janetbirdope
1 year 1 month ago
Cool technology reduces dose interval of #IL17AFi
To…every 6 to 12 months!
#Antibody ORKA-002 has end of arms w YTE substitution prolonging circulation of drug
Lasts longer than #bimekizumab
Easier for adherence!
#EULAR2025 @RheumNow @eular_org #abstPOS0016 https://t.co/KcKaIe0WMs
Dr. John Cush RheumNow
1 year 1 month ago
2025 EULAR/ACR Risk Stratification Criteria for At-Risk Arthralgia
A collaborative EULAR/ACR expert panel has established criteria for arthralgia patients at risk (clinically suspect arthralgia) to progress to chronic rheumatoid arthritis (RA). Risk stratification of CSA https://t.co/xbgJHhPqcq
Dr.Mukesh , MD , DM dr_immuno29
1 year 1 month ago
🚨 Type I IFN in Pediatric SLE: Expanded Insights!
•🩺 IFN-I Impact: Fuels pediatric SLE; drives T-cell autoreactivity, autoantibody production, proinflammatory cytokines.
•📈 Key Pathways: Plasmacytoid dendritic cells overproduce IFN-I via cGAS-STING-TBK1, TLR4/TLR9; https://t.co/4i3MktOoVd
Cristiana Sieiro Santos cristianasieiro
1 year 1 month ago
🔬 Proud to present our poster at #EULAR2025!
📌 Serum KL-6 and IL-18 as Diagnostic and Prognostic Biomarkers in Systemic Sclerosis-Associated ILD: A 24-Month Cohort Study
KL-6 and IL-18 show promising roles in tracking ILD progression and lung function decline in #SSc
📍F.136 https://t.co/woTMnTkRKY
Dr. Dinesh Khanna sclerodermaUM
1 year 1 month ago
Delighted to present the @bmsnews data on #scleroderma #eular2025. Breakfree-1 data showing CAR-T is well tolerated with beneficial effects on skin and FVC and composite endpoint, the revised CRISS. https://t.co/E5jlYYHowM
Dr. John Cush RheumNow
1 year 1 month ago
Nailfold Capillaroscopy correlated w/ cardiac ECHO in Systemic Sclerosis. NFC & ECHOs studied in 30 SSc pts. Systolic & diastolic dysfunction most common in late SSc NFC patterns. Cardiac dysfunction seen w/ low capillary density, avascular areas, cap neoangiogenesis https://t.co/pFBKjXqwfr
Dr. John Cush RheumNow
1 year 1 month ago
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty
Adela Castro AdelaCastro222
1 year 1 month ago
Phase 3 of POETYK-PsA-2:
-Deucravacitinib (oral TyK2i) met the primary endpoint of ACR20 at week 16 and was superior to placebo in multiple PsA domains.
-Clinical efficacy maintained until week 52.
-No major safety signals reported.
-Notably high placebo response rates.
Abstract
Wednesday was Day One at EULAR 2025 in Barcelona. Thousands from around the world gathered, eager to reunite at this international educational forum. Below are a few of my favorites from Day 1.
David Liew drdavidliew
1 year 1 month ago
Got paraproteinemia? Here’s what to think about, from a rheumatology point of view. @RheumNow #EULAR2025 https://t.co/eu7Mi5yeum
Adela Castro AdelaCastro222
1 year 1 month ago
POCUS of the lung can detect subclinical ILD and can be a useful, inexpensive, easy to perform screening tool for CTD-ILD.
#EULAR2025 @RheumNow https://t.co/KpH05w1S9O
Despite the advances in the treatment of PsA with biologic (bDMARD) and targeted synthetic (tsDMARD), less than half of patients with this condition achieved remission or low disease activity. Combination DMARD treatment is often used in order to achieve remission or minimal disease activity. The standard practice is to use a conventional synthetic (csDMARD) with a bDMARD. The use of the combination of bDMARD with a tsDMARD such as a JAKi or
